BRAF and non-small cell lung carcinoma: Our study focused on patients with early-stage NSCLC who had surgery and specific rare mutations including EGFR Exon20 insertion, KRAS G12C, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping, RET, and ERBB2 mutations.